Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517698 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4917523 in Patients With Fragile X Syndrome
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT01517698 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 185 participants.
The verdict
NCT01517698, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4917523 in adolescent and adult patients with fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of RO4917523, or matching placebo once daily. The anticipated time on study treatment is 12 weeks.
Interventions
- DRUG Placebo
- DRUG RO4917523 0.5 mg
- DRUG RO4917523 1.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517698
The ClinicalTrials.gov registry entry for NCT01517698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01517698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517698 about?
NCT01517698 is a clinical study titled "A Study of RO4917523 in Patients With Fragile X Syndrome". This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4917523 in adolescent and adult patients with fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of RO4917523, or matching placeb...
What is the current status of trial NCT01517698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2012-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01517698?
The interventions under investigation include: Placebo (DRUG), RO4917523 0.5 mg (DRUG), RO4917523 1.5 mg (DRUG).
Who is sponsoring clinical trial NCT01517698?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.